Halozyme Therapeutics (HALO) Projected to Release Quarterly Earnings on Thursday

Halozyme Therapeutics (NASDAQ:HALO) is projected to issue its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of $2.30 per share and revenue of $491.63 million for the quarter. Halozyme Therapeutics has set its FY 2026 guidance at 8.650-9.000 EPS. Interested persons may visit the company’s upcoming Q3 2026 earnings overview page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Halozyme Therapeutics (NASDAQ:HALO) last posted its quarterly earnings data on Thursday, August 6th. The biopharmaceutical company reported $2.28 earnings per share (EPS) for the quarter, beating the consensus estimate of $1.79 by $0.49. Halozyme Therapeutics had a return on equity of 260.98% and a net margin of 24.86%. The company had revenue of $481.00 million during the quarter, compared to analyst estimates of $402.28 million. During the same quarter last year, the company earned $1.54 earnings per share. The firm’s quarterly revenue was up 47.7% on a year-over-year basis. On average, analysts expect Halozyme Therapeutics to post $8.31 EPS for the current fiscal year and $9.79 EPS for the next fiscal year.

Halozyme Therapeutics Price Performance

Halozyme Therapeutics stock opened at $128.62 on Wednesday. The stock has a market cap of $14.60 billion, a price-to-earnings ratio of 26.16, a PEG ratio of 0.49 and a beta of 0.92. The company has a quick ratio of 2.31, a current ratio of 2.71 and a debt-to-equity ratio of 13.50. The business has a 50-day simple moving average of $114.52 and a 200 day simple moving average of $84.02. Halozyme Therapeutics has a 52 week low of $61.22 and a 52 week high of $134.00.

Wall Street Analyst Weigh In

Several brokerages have recently commented on HALO. Citizens Jmp boosted their price objective on Halozyme Therapeutics from $92.00 to $93.00 and gave the stock a “market outperform” rating in a report on Friday, August 7th. Stifel Nicolaus set a $130.00 target price on shares of Halozyme Therapeutics in a research note on Friday, October 16th. Leerink Partners raised shares of Halozyme Therapeutics from a “market perform” rating to an “outperform” rating and raised their target price for the company from $83.00 to $110.00 in a research note on Friday, August 7th. JPMorgan Chase & Co. lifted their target price on shares of Halozyme Therapeutics from $78.00 to $79.00 and gave the company a “neutral” rating in a research report on Tuesday. Finally, Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, July 21st. One investment analyst has rated the stock with a Strong Buy rating, nine have given a Buy rating, two have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $99.64.

Insider Activity at Halozyme Therapeutics

In related news, Director Matthew Posard sold 18,996 shares of the stock in a transaction on Wednesday, September 16th. The stock was sold at an average price of $107.74, for a total value of $2,046,629.04. Following the transaction, the director owned 58,839 shares of the company’s stock, valued at $6,339,313.86. This represents a 24.41% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Helen Torley sold 20,000 shares of the firm’s stock in a transaction dated Wednesday, September 9th. The shares were sold at an average price of $107.43, for a total value of $2,148,600.00. Following the sale, the chief executive officer owned 767,780 shares in the company, valued at $82,482,605.40. The trade was a 2.54% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders have sold a total of 125,852 shares of company stock valued at $13,538,046 over the last 90 days. 2.50% of the stock is owned by insiders.

Halozyme Therapeutics Company Profile

Halozyme Therapeutics, Inc is a biopharmaceutical company focused on developing and commercializing drug-delivery technologies that can improve the administration of injectable medicines. The company’s primary platform, ENHANZE, uses a proprietary recombinant human hyaluronidase enzyme to facilitate the subcutaneous delivery of biologic drugs and other injectable therapies that may otherwise require intravenous infusion.

Halozyme licenses its technologies to pharmaceutical and biotechnology companies, which use them in a range of marketed and investigational products.